SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Prometheus Biosciences, Inc. (RXDX) .
Criteria proven by this page:
- VALUE (10/100, Fail) — analyst consensus target implies downside from the current price ($138.57, 30.7%).
- Analyst consensus target $138.57 (-30.7% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 36/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
10/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — RXDX
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio1,192.58
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-3.49
Book Value / Share$0.00
Revenue / Share$0.17
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$138.57 (-30.7%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-2.18 |
$150K |
$-39.99M |
-26659.8% |
| 2016 |
$-3.44 |
$0.00 |
$-92.46M |
- |
| 2017 |
$-2.69 |
$0.00 |
$-103.64M |
- |
| 2020 |
$-1.13 |
$1.12M |
$-30.49M |
-2727.5% |
| 2021 |
$-1.13 |
$1.23M |
$-39.25M |
-3193.9% |
| 2022 |
$-2.87 |
$3.13M |
$-89.94M |
-2874.3% |
| 2023 |
$-3.49 |
$6.81M |
$-141.75M |
-2081.8% |
